According to the company, DXLr120 significantly improves antibodies binding to CD20, the target for non Hodgkin’s lymphoma and rheumatoid arthritis and joins InNexus’s DXL625 (CD20). DXL625, developed with chemical methods, also significantly improves the binding of antibodies to CD20 and increases potency using both in vitro and in vivo studies.
Preliminary data for DXLr120 already reveals properties akin to those shown for DXL625. Plans are underway to subject DXLr120 to the full battery of tests for potency, in vivo efficacy and safety used for DXL625.
Thomas Kindt, InNexus chief scientific officer, said: “Use of recombinant methods to develop DXLr120 with our patented DXL technology demonstrates the expertise of our team and the opportunity we have to create multiple therapeutic and diagnostic antibodies.”